Affluent Medical appoints Liane Teplitsky - a senior executive in the medical device industry as a new member of the Board of Directors
|
EQS-News: Affluent Medical SA
/ Key word(s): Personnel
Affluent Medical appoints Liane Teplitsky - a senior executive in the medical device industry as a new member of the Board of Directors Aix-en-Provence, February 25, 2025 – 5:45 p.m. CET – Affluent Medical (ISIN: FR0013333077 – Ticker: AFME – “Affluent”), a French clinical-stage medical technology company specializing in the international development and industrialization of innovative implantable medical devices, today announced it has coopted Liane Teplitsky as a new Board member. Recently appointed CEO of Artedrone, the first autonomous robotic solution for Mechanical Thrombectomy, Liane Teplitsky is a successful seasoned senior executive in the medical device with achievements in building, leading, and growing innovative businesses that elevate the standard of patient care. With an extensive background in R&D and a passion for advancing intelligent and life-changing medical technologies, Liane has cultivated an expertise in leading business strategy, clinical data development and commercialization for multimillion-dollar global medical technology franchises. Additionally, Liane has demonstrated excellence in building and leading highly functioning, highly engaged teams. Most recently she was President, Global Robotics, Technology & Data Solutions at Zimmer Biomet where she led the global growth and development of the company’s portfolio of robotics and digital health technologies. Prior to Zimmer Biomet, Liane spent nearly a decade in executive leadership roles at Abbott as Vice President Sales & Division Vice President Marketing for Cardiac Arrhythmia & Heart Failure division and at St Jude Medical, with different strategic roles across multiple product and sales divisions. Liane holds a Master of Science in Biomedical Engineering from Duke University and a Bachelor of Science in Electrical Engineering and a Bachelor of Science in Physiology from the University of Saskatchewan - Canada. Sébastien Ladet, Affluent Medical CEO declares: “We are excited to welcome Liane to our board of Directors. Her extensive experience in both the healthcare and technology sectors, combined with her proven track record in leading market development and sales for medical devices, will be invaluable as we continue to advance in the clinical development of our 2 cutting-hedge medical devices to treat mitral valve regurgitation and prepare for their commercialisation.” About Affluent Medical Affluent Medical is a French medical technologies company, founded by Truffle Capital, that aims to become a global leader in the treatment of structural heart diseases, one of the world's leading causes of mortality, and urinary incontinence, which currently affects one in four adults. Affluent Medical develops next-generation implants that are minimally invasive, innovative, adjustable and biomimetic, designed to restore essential physiological functions. The candidate products developed by the Company are all undergoing clinical studies in humans. Subject to raising the funds necessary to finance its strategy and the positive results of ongoing clinical studies, the Company aims to gradually market its products from 2026, directly or indirectly. For more information, please visit www.affluentmedical.com Contacts:
25.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Affluent Medical SA |
| 320 avenue Archimède - Les pléiades III Batiment B | |
| 13100 Aix-en-Provence | |
| France | |
| E-mail: | affluent@mc-services.eu |
| Internet: | www.affluentmedical.com |
| ISIN: | FR0013333077 |
| EQS News ID: | 2091127 |
| End of News | EQS News Service |
|
|
2091127 25.02.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.